International Journal of Radiation Oncology*Biology*Physics, 10/2017, Vol.99(2), S, p.E107
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ijrobp.2017.06.850 Byline: D.D. Shi (1)(2), N.D. Arvold (3)(4), A.A. Aizer (2), A.D. Norden (2), D.A. Reardon (1)(5), E.Q. Lee (2), L. Nayak (2), I.F. Dunn (2), A.J. Golby (2), M.D. Johnson (2), E.B. Claus (2)(6), A. Chiocca (2), K.L. Ligon (2), P. Wen (7), B.M. Alexander (7) Author Affiliation: (1) Harvard Medical School, Boston, MA (2) Dana-Farber/Brigham and Women's Cancer Center, Boston, MA (3) St. Luke's Cancer Center, and Whiteside Institute for Clinical Research, Duluth, MN (4) University of Minnesota Duluth, Duluth, MN (5) Dana-Farber Cancer Institute and Harvard University School of Medicine, Boston, MA (6) Yale University School of Public Health, New Haven, CT (7) Dana-Farber Cancer Institute, Brigham and Women's Cancer Center, Boston, MA Article Note: (footnote) Author Disclosure: D.D. Shi: None. N.D. Arvold: None. A.A. Aizer: None. A.D. Norden: Consultant; BMS, Celldex, Vascular Biogenics. D.A. Reardon: Research Grant; Celldex, Inovio, Midatech. Speaker's Bureau; Merck/Schering, Roche/Genentech. Advisory Board; Abbvie, Bristol Myers Squibb, Cavion, Celldex, EMD Serono, Juno Pharmaceuticals, Momenta Pharmaceuticals, Novartis, Novocure, Oxigene, Regeneron, Roche/Genentech, Stemline. E.Q. Lee: Consultant; Roche/Genentech. L. Nayak: Consultant; Amgen. I.F. Dunn: None. A.J. Golby: None. M.D. Johnson: None. E.B. Claus: None. A. Chiocca: None. K.L. Ligon: None. P. Wen: Consultant; Agios, Angiochem. Advisory Board; AbbVie, Astra Zeneca, Cavion. B.M. Alexander: Honoraria; Schlesenger Associates. Consultant; Abbvie, Bristol Myers Squibb.
Gliomas – Analysis ; Medical Schools – Analysis ; Angiogenesis Inhibitors – Analysis;